Miniaturization & Microfluidics
This article was originally published in Start Up
Executive Summary
Venture capitalists have been pouring money into start-up companies who promise to shrink, speed, and reduce the cost of any and all bioanalytical processes. Their target markets are drug screening, where throughput is prized; and diagnostics, where miniaturization brings portability and opportunities in point-of-care testing.